论文部分内容阅读
米托蒽醌(Mitoxantrone,Novantrone,DHAD,下简称M)在13届国际化疗会议中曾被推荐为治疗乳腺癌的一线药物,本届会议对M 进行了专题讨论。日本三个协作组的临床研究证实,M 对急性非粒细胞白血病、非何杰金氏淋巴肉瘤和乳腺癌均有效。对乳腺癌所用剂量较低,疗效略低于欧美报道者。在曾用过化疗的乳腺癌患者中,M+Mito C 的有效率为24%,M+Mi-to C+VCR 为46%,M+VCR 为19%;对未经化疗的晚期病人,M+CTX 的平均有效率为48%、M+CTX+5-Fu 为70%,M+三苯氧胺为100%(仅6例)。
Mitoxantrone (Novantrone, DHAD, hereinafter referred to as M) was recommended as the first-line drug for the treatment of breast cancer at the 13th International Conference on Chemotherapy. This session conducted a special discussion on M. Clinical studies in three Japanese collaboration groups confirmed that M is effective against acute non-granulocytic leukemia, non-Hodgkin’s lymphosarcoma, and breast cancer. The use of low doses of breast cancer, the effect is slightly lower than those in Europe and the United States. In breast cancer patients who had been treated with chemotherapy, the effective rate of M+Mito C was 24%, M+Mi-to C+VCR was 46%, and M+VCR was 19%; for advanced patients who had not been treated with chemotherapy, M The average effective rate of +CTX was 48%, 70% for M+CTX+5-Fu, and 100% for M+ tamoxifen (only 6 cases).